The clients who arrive at Holina with a benzodiazepine problem rarely think of it that way at first. They began with a doctor’s prescription, written for sleep or anxiety or panic, often after a clearly difficult period in their life. The medication worked, in the short term, in the way it was designed to. And then, somewhere across the following months or years, the relationship to the medication quietly shifted. The dose required for the same effect rose. Missing a day produced a symptom worse than the one the medication was originally treating. The line between treatment and dependence became, for them, invisible.
This is the most common presentation of benzodiazepine dependence we see, and it is also one of the most clinically delicate. Benzodiazepines are unlike most substances in addiction medicine: the withdrawal from chronic use can be genuinely dangerous, the timeline of safe discontinuation is long, and many commonly available detox protocols, even at credible facilities, are calibrated to a faster schedule than the medication actually allows. This piece is for clients and families trying to understand why the slow taper matters, and what it looks like done well.
What Benzodiazepine Dependence Actually Is
The scale of the benzodiazepine picture has shifted markedly over the past two decades. CDC surveillance data tracking 2019–2020 found that nonfatal benzodiazepine-involved emergency department visits rose by nearly a quarter year-on-year, that fatal benzodiazepine overdoses rose by more than 40% over the same comparison period, and that deaths involving illicitly-manufactured benzodiazepines increased more than fivefold — with the large majority of benzodiazepine deaths also involving opioids.1 The Ashton Manual, written by the British psychiatrist Professor C. Heather Ashton, remains the most widely-referenced clinical guide for the slow-taper approach and is the schedule most of the addiction medicine field still works from today.2
Benzodiazepines — Xanax, Valium, Klonopin, Ativan, Lorazepam, Temazepam, and several others — work by enhancing the activity of GABA, the brain’s primary inhibitory neurotransmitter. The effect is calming, and in the right contexts, genuinely useful for short-term management of acute anxiety, panic, sleep disturbance, and certain seizure disorders. The trouble begins with sustained use. Within weeks to months, the brain adjusts its own GABA system in response to the additional input, reducing its native production and altering receptor sensitivity. By the time someone has been on a benzodiazepine for six months continuously, the underlying neurochemistry has changed.
What this means in practice is that the person is no longer in the same body that began the medication. Stopping abruptly does not return the system to its pre-medication baseline. It exposes the now-adjusted system to its own undermedicated state, and the resulting withdrawal is what makes benzodiazepine cessation clinically distinctive.
Why Benzodiazepine Withdrawal Is Different
Most addiction withdrawal, while uncomfortable, is not medically dangerous in adults without other significant health conditions. Alcohol withdrawal at the severe end is, alongside benzodiazepine withdrawal, the exception. Clinical literature on benzodiazepine discontinuation is clear that after roughly one to six months of regular use, abrupt cessation can cause seizures, delirium, and in rare cases death — which is why gradual, supervised tapering rather than sudden discontinuation is the standard clinical recommendation.3 Stopping a chronic benzodiazepine suddenly can also produce severe autonomic instability, prolonged insomnia, panic states that meaningfully exceed the original anxiety, and a constellation of neurological symptoms — visual disturbances, tinnitus, derealisation, muscle rigidity — that can persist for weeks or months in some individuals.
The phenomenon is well-documented in the clinical literature and goes by several names: protracted withdrawal, post-acute withdrawal syndrome from benzodiazepines, or in the patient communities that have organised around it, the Ashton Protocol, after the British psychiatrist Heather Ashton who developed the most widely-referenced tapering schedule.2
The central clinical insight is that the brain’s GABA system takes far longer to recalibrate than the medication takes to leave the body. The half-life of most benzodiazepines is days at most. The recovery of native GABA function can take many months. A taper that moves faster than this recovery curve tends to produce sustained withdrawal symptoms; a taper that respects it allows the system to adjust at the pace it can actually manage.
Why Most Detoxes Get the Timing Wrong
Standard residential detox protocols at most facilities are built around alcohol and opioid presentations, where the acute medical withdrawal window is typically shorter and a standard residential stay can encompass it. Benzodiazepine detox, when conducted at the pace the medication actually warrants, can take considerably longer — often several weeks and, for long-term or high-dose use, months.
This is, simply, longer than many standard residential windows. The result, at many facilities, is one of three patterns. Some facilities do a faster taper than the medication warrants, producing withdrawal symptoms that the client misattributes to underlying anxiety and that often drive return to use after discharge. Some facilities decline benzodiazepine admissions altogether, referring the client elsewhere. Some facilities take the client on, do the early stabilisation well, and then discharge before the taper is anywhere near complete, expecting outpatient continuation that frequently does not happen.
None of these patterns is malicious. They are, in most cases, the consequence of trying to fit a benzodiazepine presentation into a treatment structure that was not designed for it.
“Since coming to Holina, I have been sober and, miraculously, my obsession with alcohol has been lifted.”
— Rodney B, Recovery.com Review, 25 Mar 2025 · ★★★★★
What the Slow Taper Actually Looks Like
A well-conducted benzodiazepine taper typically begins with a cross-titration onto a longer-acting benzodiazepine, most commonly diazepam, which is then reduced in small, evenly-spaced decrements over an extended schedule.2,3 The decrement size and the spacing between reductions depend on the original dose, the duration of use, the client’s response to early reductions, and the presence of any complicating conditions.
A reasonable taper for a client who has been on a moderate dose of a short-acting benzodiazepine for several years might look like a five to ten percent reduction every two to three weeks, with longer holds when symptoms emerge and resumption only once stability returns. This is not a fast process. It is, in clinical terms, closer to the pace the medication actually requires.
What makes the work possible in a residential setting is the surrounding support — sleep architecture restoration, nutritional support, somatic and nervous system regulation work, the gentle treatment of the underlying anxiety or trauma that the medication was originally prescribed for, and the continuous clinical attention that allows decrements to be adjusted in real time rather than according to a fixed schedule.
The Underlying Condition Almost Always Matters
Benzodiazepine dependence is rarely the whole picture. The original prescription was, in most cases, for something — panic disorder, generalised anxiety, complex trauma, treatment-resistant insomnia. The medication has been suppressing the surface symptoms of that condition for years, in some cases. As the taper progresses, the underlying condition often resurfaces, sometimes in forms the client has not consciously felt in a long time.
This is a clinical opportunity, not a complication. The work that the medication was substituting for can finally be done. Trauma processing, where indicated, can address the substrate of the original anxiety. Somatic and nervous-system-focused therapies can begin to do, in months, what the medication has been doing chemically for years. Where the underlying condition is well-treated during the taper, the post-taper outcome tends to be meaningfully better than where the taper is conducted as a chemistry problem alone.
This is the principal reason that benzodiazepine work belongs in a setting that integrates medical detox with deeper psychotherapeutic and somatic care, rather than in a setting that is purely a medical detox unit.
“The families who come to us worried about a loved one’s benzodiazepine dose are rarely dealing with someone who set out to misuse a medication. They’re dealing with a nervous system that adapted to a drug exactly as it was designed to, and now needs the time to adapt back. Rushing that process is where real medical risk creeps in.”
What a Realistic Holina Admission Looks Like
For benzodiazepine presentations specifically, we typically recommend longer admissions than for alcohol or stimulant presentations. A 60-day residential program is the minimum we would generally consider for moderate dependence on shorter-acting benzodiazepines; 90 days is more appropriate for longer-duration use, higher doses, or polysubstance presentations involving benzodiazepines alongside alcohol or opioids. In some cases, a residential program is followed by an extended outpatient or sober-living taper continuation, which may add several months to the total work.
This is not a length families typically arrive expecting. It is, however, closer to the length the medication itself requires for a taper that is both safe and sustainable. In our clinical experience, we have met fewer benzodiazepine clients who regretted the longer admission than we have met who regretted the shorter one. The taper that is rushed is more likely to be followed by a return to use. The taper that is given its time is more often sustained. Families weighing the cost of a longer admission are welcome to speak with our team about financing and insurance options.
A Closing Note for Clients Currently on Benzodiazepines
If you are reading this and recognising your own pattern, the most important thing to know is that the issue is not a moral failure. Benzodiazepine dependence is, in most cases, the chemical consequence of taking a working medication for longer than it was designed to be taken. The dependence is real, and so is the discomfort of coming off. Neither is shameful, and both are addressable in a setting calibrated to the actual demands of the work.
Do not stop your medication abruptly. Do not attempt a fast taper without clinical supervision. Benzodiazepine withdrawal that is mismanaged can, in some cases, become the trauma that the next decade of recovery work has to address. Benzodiazepine withdrawal that is managed well becomes a finite, contained, demanding piece of work that ends — and beyond which a meaningfully different life is available.
Holina’s clinical team will speak with you and your prescribing physician about a path that fits your specific medication, dose, and history. Families are also welcome to reach out through our family support programme while that planning happens. The first call is the beginning of the planning, not the beginning of the taper itself. Contact our clinical team to start that conversation.
Sources:
1. “Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines — 38 States and the District of Columbia, 2019–2020,” CDC MMWR, 2021.
2. Ashton, C.H., “Benzodiazepines: How They Work and How to Withdraw” (the Ashton Manual), benzo.org.uk.
3. “Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation,” Therapeutic Advances in Psychopharmacology / PMC, 2018.
Related Reading
Ready to Start Your Recovery Journey?
Our clinical team is available to answer your questions and help you find the right programme for your needs.
Speak with Our Team →